Voyager Therapeutics, Inc. (VYGR)
2.14
-0.13
(-5.73%)
USD |
NASDAQ |
Oct 13, 16:00
2.19
+0.05
(+2.34%)
After-Hours: 19:22
Voyager Therapeutics Enterprise Value : 55.32M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 55.32M |
| October 09, 2026 | 66.35M |
| October 08, 2026 | 61.45M |
| October 07, 2026 | 67.57M |
| October 06, 2026 | 66.96M |
| October 05, 2026 | 66.96M |
| October 02, 2026 | 66.35M |
| October 01, 2026 | 80.14M |
| September 30, 2026 | 80.44M |
| September 29, 2026 | 77.99M |
| September 28, 2026 | 81.67M |
| September 25, 2026 | 80.44M |
| September 24, 2026 | 87.79M |
| September 23, 2026 | 92.08M |
| September 22, 2026 | 108.63M |
| September 21, 2026 | 104.95M |
| September 18, 2026 | 105.56M |
| September 17, 2026 | 102.50M |
| September 16, 2026 | 103.11M |
| September 15, 2026 | 105.56M |
| September 14, 2026 | 111.69M |
| September 11, 2026 | 111.69M |
| September 10, 2026 | 111.69M |
| September 09, 2026 | 115.37M |
| September 08, 2026 | 124.56M |
| Date | Value |
|---|---|
| September 04, 2026 | 131.30M |
| September 03, 2026 | 123.33M |
| September 02, 2026 | 133.14M |
| September 01, 2026 | 126.40M |
| August 31, 2026 | 127.62M |
| August 28, 2026 | 133.14M |
| August 27, 2026 | 128.24M |
| August 26, 2026 | 128.24M |
| August 25, 2026 | 129.46M |
| August 24, 2026 | 127.01M |
| August 21, 2026 | 123.95M |
| August 20, 2026 | 119.66M |
| August 19, 2026 | 125.17M |
| August 18, 2026 | 118.43M |
| August 17, 2026 | 114.14M |
| August 14, 2026 | 116.59M |
| August 13, 2026 | 113.53M |
| August 12, 2026 | 112.30M |
| August 11, 2026 | 112.30M |
| August 10, 2026 | 110.47M |
| August 07, 2026 | 116.59M |
| August 06, 2026 | 108.01M |
| August 05, 2026 | 106.18M |
| August 04, 2026 | 107.71M |
| August 03, 2026 | 100.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 269.05B |
| Anika Therapeutics, Inc. | 260.79M |
| BioCryst Pharmaceuticals, Inc. | 2.618B |
| Imunon, Inc. | 5.973M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.47M |
| Revenue (Quarterly) | 3.165M |
| Total Expenses (Quarterly) | 27.64M |
| EPS Diluted (Quarterly) | -0.4042 |
| Gross Profit Margin (Quarterly) | 71.31% |
| Profit Margin (Quarterly) | -773.2% |
| Earnings Yield | -84.74% |
| Normalized Earnings Yield | -84.74 |